KR20220098175A - B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합 - Google Patents

B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합 Download PDF

Info

Publication number
KR20220098175A
KR20220098175A KR1020227018891A KR20227018891A KR20220098175A KR 20220098175 A KR20220098175 A KR 20220098175A KR 1020227018891 A KR1020227018891 A KR 1020227018891A KR 20227018891 A KR20227018891 A KR 20227018891A KR 20220098175 A KR20220098175 A KR 20220098175A
Authority
KR
South Korea
Prior art keywords
administered
acalabrutinib
formula
pharmaceutically acceptable
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227018891A
Other languages
English (en)
Korean (ko)
Inventor
한나 드라이
브랜든 윌리스
앤드류 블뢰허
제롬 메테탈
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20220098175A publication Critical patent/KR20220098175A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227018891A 2019-11-04 2020-10-30 B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합 Pending KR20220098175A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
US62/930,208 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (1)

Publication Number Publication Date
KR20220098175A true KR20220098175A (ko) 2022-07-11

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018891A Pending KR20220098175A (ko) 2019-11-04 2020-10-30 B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합

Country Status (14)

Country Link
US (1) US20220401442A1 (https=)
EP (1) EP4054582B1 (https=)
JP (1) JP7575454B2 (https=)
KR (1) KR20220098175A (https=)
CN (1) CN114728003B (https=)
AU (1) AU2020381240C1 (https=)
CA (1) CA3158321A1 (https=)
DK (1) DK4054582T3 (https=)
ES (1) ES3055126T3 (https=)
FI (1) FI4054582T3 (https=)
MX (1) MX2022005250A (https=)
PL (1) PL4054582T3 (https=)
PT (1) PT4054582T (https=)
WO (1) WO2021089419A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
KR20250105657A (ko) * 2022-11-15 2025-07-08 아스트라제네카 아베 카피바설팁과 베네토클락스의 치료적 조합

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
EP3689878B1 (en) 2011-07-19 2021-10-06 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
KR20160090903A (ko) * 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
CN105979948A (zh) * 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
US20180353512A1 (en) * 2015-06-23 2018-12-13 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
CU20180059A7 (es) * 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2019058348A1 (en) * 2017-09-25 2019-03-28 Astrazeneca Ab COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合

Also Published As

Publication number Publication date
CN114728003B (zh) 2025-01-28
DK4054582T3 (da) 2025-12-01
US20220401442A1 (en) 2022-12-22
WO2021089419A1 (en) 2021-05-14
ES3055126T3 (en) 2026-02-10
PL4054582T3 (pl) 2026-02-16
CA3158321A1 (en) 2021-05-14
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
EP4054582B1 (en) 2025-09-03
PT4054582T (pt) 2025-12-10
CN114728003A (zh) 2022-07-08
EP4054582A1 (en) 2022-09-14
FI4054582T3 (fi) 2025-12-04
AU2020381240B2 (en) 2023-09-07
AU2020381240A1 (en) 2022-06-23
AU2020381240C1 (en) 2024-02-15
MX2022005250A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
US9421208B2 (en) Methods for the treatment of solid tumors
TWI607754B (zh) 醫藥組合
ES2992423T3 (es) Nuevo uso del agonista del receptor de angiotensina II tipo 2
JP7111811B2 (ja) がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
JP7703124B1 (ja) Ｓｅｒｄ投薬レジメンの組み合わせを使用してがんを治療する方法
JP7575454B2 (ja) Ｂ細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
HK40069821B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
EA045670B1 (ru) Терапевтические комбинации акалабрутиниба и капивасертиба для лечения в-клеточных злокачественных образований
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
EP4364742A1 (en) Pharmaceutical composition for treating solid tumors
WO2006012958A2 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
TWI922738B (zh) 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途
US11911374B2 (en) Methods and uses for treating cancer
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
JP2025533900A (ja) エストロゲン受容体媒介性障害を治療する方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000